<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-37204-2S4</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Super antibodies as a weapon against HIV-1</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Antibodies are a very important part of the immune response against HIV. In the past there has been a strong distinction between antibodies that can neutralize free virus to prevent infection and antibodies that can activate other immune cells to kill the already infected cells. Not many scientists have studied the combination of the different functions by one antibody at the same time. In this project, an antibody, that can very potently neutralize HIV, will be
modified to gain additional functions to also kill HIV infected cells. These novel super antibodies could have the potential to be use as an alternative</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The aim of the proposed project is to create super antibodies from known HIV-specific bNAbs. The combination of both broad neutralization and effector function by antibodies can be very beneficial, as these antibodies can block infection and at the same
time mediate the killing of infected cells. The ability of potentneutralizing antibodies to also have Fc- mediated effector functions can progress the field further and could even be part of a future cure
in the &#x2018;shock and kill&#x2019; approach, where the super antibodies will kill the activated cells.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">The immune system has many ways to tackle dangerous pathogens, and one way are antibodies, which are the essential part of the humoral arm of the immune system. They have a wide-range of functions including pathogen neutralization, complement activation and cell lysis. I and others have shown that HIV-infected individuals can develop potent broadly neutralizing antibodies (bNAbs) against HIV. These bNAbs have shown to protect against HIV-infection, however the use of bNAbs as therapeutic agents has not yielded the desired prolonged suppression of virus replication so far, indicating that other antibody functions might be necessary for therapeutic applications.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">This project will first reach other scientists in the fields of antibody engineering, HIV therapeutics and HIV cure.

End beneficiaries: People living with HIV</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2018-10-01" type="1"></activity-date>
  <activity-date iso-date="2019-12-31" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Super antibodies as a weapon against HIV-1 STD control including HIV/AIDS</narrative>
  </sector>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Super antibodies as a weapon against HIV-1 STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2018-10-01"></period-start>
   <period-end iso-date="2019-12-31"></period-end>
   <value currency="EUR" value-date="2018-10-01">75000</value>
  </budget>
  <transaction>
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2018-05-31"></transaction-date>
   <value currency="EUR" value-date="2018-05-31">6853</value>
   <description>
    <narrative xml:lang="EN">Opbrengst ADD 2018 voor High Risk High Gain Onderzoek: &#x20AC;136.293

Gelijk verdeeld over dit project en P-37102 (A novel gene therapy approach to cure HIV); 

bijdrage AmsterdamDiner Foundation aan P-37204 &#x20AC;68.146,50

bijdrage Aidsfonds aan P-37204 &#x20AC;6853,50</narrative>
   </description>
   <provider-org provider-activity-id="NL-KVK-41207989-" ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">67500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">67500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-07-27"></transaction-date>
   <value currency="EUR" value-date="2020-07-27">7500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-07-28"></transaction-date>
   <value currency="EUR" value-date="2020-07-28">7500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2018-05-31"></transaction-date>
   <value currency="EUR" value-date="2018-05-31">68147</value>
   <provider-org provider-activity-id="NL-KVK-412115640001-" ref="NL-KVK-412115640001">
    <narrative xml:lang="EN">AmsterdamDiner Foundation</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
